Repros Therapeutics Inc. (NASDAQ:RPRX) is scheduled to be posting its quarterly earnings results before the market opens on Monday, November 6th. Analysts expect Repros Therapeutics to post earnings of ($0.28) per share for the quarter.

Repros Therapeutics (NASDAQ:RPRX) last issued its earnings results on Monday, August 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.14. The company had revenue of $0.01 million for the quarter. Repros Therapeutics had a negative return on equity of 412.64% and a negative net margin of 56,062.07%. On average, analysts expect Repros Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of Repros Therapeutics Inc. (NASDAQ RPRX) opened at 0.5499 on Monday. The company’s 50-day moving average price is $0.42 and its 200 day moving average price is $0.51. The company’s market cap is $20.68 million. Repros Therapeutics Inc. has a 52 week low of $0.26 and a 52 week high of $2.15.

Separately, Laidlaw cut Repros Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, July 21st.

COPYRIGHT VIOLATION WARNING: “Repros Therapeutics Inc. (RPRX) Scheduled to Post Earnings on Monday” was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/30/repros-therapeutics-inc-rprx-scheduled-to-post-earnings-on-monday-2.html.

Repros Therapeutics Company Profile

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Earnings History for Repros Therapeutics (NASDAQ:RPRX)

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.